Ozempic

Nchi: Umoja wa Ulaya

Lugha: Kiingereza

Chanzo: EMA (European Medicines Agency)

Nunua Sasa

Taarifa za kipeperushi Taarifa za kipeperushi (PIL)
03-05-2023
Tabia za bidhaa Tabia za bidhaa (SPC)
03-05-2023

Viambatanisho vya kazi:

semaglutide

Inapatikana kutoka:

Novo Nordisk A/S

ATC kanuni:

A10BJ06

INN (Jina la Kimataifa):

semaglutide

Kundi la matibabu:

Drugs used in diabetes

Eneo la matibabu:

Diabetes Mellitus

Matibabu dalili:

Treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise:as monotherapy when metformin is considered inappropriate due to intolerance or contraindications;in addition to other medicinal products for the treatment of diabetes.For study results with respect to combinations, effects on glycaemic control and cardiovascular events, and the populations studied, see sections 4.4, 4.5 and 5.1.

Bidhaa muhtasari:

Revision: 10

Idhini hali ya:

Authorised

Idhini ya tarehe:

2018-02-08

Taarifa za kipeperushi

                                45
B. PACKAGE LEAFLET
46
PACKAGE LEAFLET: INFORMATION FOR THE PATIENT
OZEMPIC 0.25 MG SOLUTION FOR INJECTION IN PRE-FILLED PEN
semaglutide
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
–
Keep this leaflet. You may need to read it again.
–
If you have any further questions, ask your doctor, pharmacist or
nurse.
–
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.
–
If you get any side effects, talk to your doctor, pharmacist or nurse.
This includes any possible side
effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What Ozempic is and what it is used for
2.
What you need to know before you use Ozempic
3.
How to use Ozempic
4.
Possible side effects
5.
How to store Ozempic
6.
Contents of the pack and other information
1.
WHAT OZEMPIC IS AND WHAT IT IS USED FOR
Ozempic contains the active substance semaglutide. It
_ _
helps your body reduce your blood sugar level
only when blood sugar is too high and can help prevent heart disease.
Ozempic is used to treat adults (aged 18 years and older) with type 2
diabetes when diet and exercise
is not enough:
•
on its own – when you cannot use metformin (another diabetes
medicine) or
•
with other medicines for diabetes – when they are not enough to
control your blood sugar levels.
These may be medicines you take by mouth or inject such as insulin.
It is important that you continue with your diet and exercise plan as
told by your doctor, pharmacist or
nurse.
2.
WHAT YOU NEED TO KNOW BEFORE YOU USE OZEMPIC
_ _
DO NOT USE OZEMPIC
•
if you are allergic to semaglutide or any of the other ingredients of
this medicine (listed in
section 6).
WARNINGS AND PRECAUTIONS
Talk to your doctor, pharmacist or nurse before using this medicine.
This medicine is not the same as insulin and you should not use it if:
•
you have type 1 diabetes – a condition where your body does no
                                
                                Soma hati kamili
                                
                            

Tabia za bidhaa

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
Ozempic 0.25 mg solution for injection in pre-filled pen
Ozempic 0.5 mg solution for injection in pre-filled pen
Ozempic 1 mg solution for injection in pre-filled pen
Ozempic 2 mg solution for injection in pre-filled pen
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Ozempic 0.25 mg
solution for injection
One ml of solution contains 1.34 mg of semaglutide*. One pre-filled
pen contains 2 mg semaglutide*
in 1.5 ml solution. Each dose contains 0.25 mg of semaglutide in 0.19
ml solution.
Ozempic 0.5 mg solution for injection
One ml of solution contains 1.34 mg of semaglutide*. One pre-filled
pen contains 2 mg semaglutide*
in 1.5 ml solution. Each dose contains 0.5 mg of semaglutide in 0.37
ml solution.
Ozempic 1 mg solution for injection
One ml of solution contains 1.34 mg of semaglutide*. One pre-filled
pen contains 4 mg semaglutide*
in 3 ml solution. Each dose contains 1 mg of semaglutide in 0.74 ml
solution.
Ozempic 2 mg solution for injection
One ml of solution contains 2.68 mg of semaglutide*. One pre-filled
pen contains 8 mg semaglutide*
in 3 ml solution. Each dose contains 2 mg of semaglutide in 0.74 ml
solution.
*Human glucagon-like peptide-1 (GLP-1) analogue produced in
_Saccharomyces cerevisiae _
cells
_ _
by
_ _
recombinant DNA technology
_._
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Solution for injection (injection).
Clear and colourless or almost colourless, isotonic solution; pH=7.4.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Ozempic is indicated for the treatment of adults with insufficiently
controlled type 2 diabetes mellitus
as an adjunct to diet and exercise
•
as monotherapy when metformin is considered inappropriate due to
intolerance or
contraindications
•
in addition to other medicinal products for the treatment of diabetes.
3
For trial results with respect to combinations, effects on glycaemic
control and cardiovascular events,
and the populations studied, see sections 4.4, 
                                
                                Soma hati kamili
                                
                            

Nyaraka katika lugha zingine

Taarifa za kipeperushi Taarifa za kipeperushi Kibulgaria 03-05-2023
Tabia za bidhaa Tabia za bidhaa Kibulgaria 03-05-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kibulgaria 21-02-2018
Taarifa za kipeperushi Taarifa za kipeperushi Kihispania 03-05-2023
Tabia za bidhaa Tabia za bidhaa Kihispania 03-05-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kihispania 21-02-2018
Taarifa za kipeperushi Taarifa za kipeperushi Kicheki 03-05-2023
Tabia za bidhaa Tabia za bidhaa Kicheki 03-05-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kicheki 21-02-2018
Taarifa za kipeperushi Taarifa za kipeperushi Kidenmaki 03-05-2023
Tabia za bidhaa Tabia za bidhaa Kidenmaki 03-05-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kidenmaki 21-02-2018
Taarifa za kipeperushi Taarifa za kipeperushi Kijerumani 03-05-2023
Tabia za bidhaa Tabia za bidhaa Kijerumani 03-05-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kijerumani 21-02-2018
Taarifa za kipeperushi Taarifa za kipeperushi Kiestonia 03-05-2023
Tabia za bidhaa Tabia za bidhaa Kiestonia 03-05-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kiestonia 21-02-2018
Taarifa za kipeperushi Taarifa za kipeperushi Kigiriki 03-05-2023
Tabia za bidhaa Tabia za bidhaa Kigiriki 03-05-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kigiriki 21-02-2018
Taarifa za kipeperushi Taarifa za kipeperushi Kifaransa 03-05-2023
Tabia za bidhaa Tabia za bidhaa Kifaransa 03-05-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kifaransa 21-02-2018
Taarifa za kipeperushi Taarifa za kipeperushi Kiitaliano 03-05-2023
Tabia za bidhaa Tabia za bidhaa Kiitaliano 03-05-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kiitaliano 21-02-2018
Taarifa za kipeperushi Taarifa za kipeperushi Kilatvia 03-05-2023
Tabia za bidhaa Tabia za bidhaa Kilatvia 03-05-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kilatvia 21-02-2018
Taarifa za kipeperushi Taarifa za kipeperushi Kilithuania 03-05-2023
Tabia za bidhaa Tabia za bidhaa Kilithuania 03-05-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kilithuania 21-02-2018
Taarifa za kipeperushi Taarifa za kipeperushi Kihungari 03-05-2023
Tabia za bidhaa Tabia za bidhaa Kihungari 03-05-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kihungari 21-02-2018
Taarifa za kipeperushi Taarifa za kipeperushi Kimalta 03-05-2023
Tabia za bidhaa Tabia za bidhaa Kimalta 03-05-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kimalta 21-02-2018
Taarifa za kipeperushi Taarifa za kipeperushi Kiholanzi 03-05-2023
Tabia za bidhaa Tabia za bidhaa Kiholanzi 03-05-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kiholanzi 21-02-2018
Taarifa za kipeperushi Taarifa za kipeperushi Kipolandi 03-05-2023
Tabia za bidhaa Tabia za bidhaa Kipolandi 03-05-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kipolandi 21-02-2018
Taarifa za kipeperushi Taarifa za kipeperushi Kireno 03-05-2023
Tabia za bidhaa Tabia za bidhaa Kireno 03-05-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kireno 21-02-2018
Taarifa za kipeperushi Taarifa za kipeperushi Kiromania 03-05-2023
Tabia za bidhaa Tabia za bidhaa Kiromania 03-05-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kiromania 21-02-2018
Taarifa za kipeperushi Taarifa za kipeperushi Kislovakia 03-05-2023
Tabia za bidhaa Tabia za bidhaa Kislovakia 03-05-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kislovakia 21-02-2018
Taarifa za kipeperushi Taarifa za kipeperushi Kislovenia 03-05-2023
Tabia za bidhaa Tabia za bidhaa Kislovenia 03-05-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kislovenia 21-02-2018
Taarifa za kipeperushi Taarifa za kipeperushi Kifinlandi 03-05-2023
Tabia za bidhaa Tabia za bidhaa Kifinlandi 03-05-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kifinlandi 21-02-2018
Taarifa za kipeperushi Taarifa za kipeperushi Kiswidi 03-05-2023
Tabia za bidhaa Tabia za bidhaa Kiswidi 03-05-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kiswidi 21-02-2018
Taarifa za kipeperushi Taarifa za kipeperushi Kinorwe 03-05-2023
Tabia za bidhaa Tabia za bidhaa Kinorwe 03-05-2023
Taarifa za kipeperushi Taarifa za kipeperushi Kiaisilandi 03-05-2023
Tabia za bidhaa Tabia za bidhaa Kiaisilandi 03-05-2023
Taarifa za kipeperushi Taarifa za kipeperushi Kroeshia 03-05-2023
Tabia za bidhaa Tabia za bidhaa Kroeshia 03-05-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kroeshia 21-02-2018

Tafuta arifu zinazohusiana na bidhaa hii

Tazama historia ya hati